EMD Biosciences, Inc. And MorphoSys AG' Antibodies By Design Offer First Recombinant Antibody; For Detection Of Cyclophilin A, A Component Of Protein Folding
10/19/2005 5:12:17 PM
EMD Biosciences, Inc. (EMD Biosciences; www.emdbiosciences.com), a major supplier of premium tools for proteomics and disease pathway analysis known through its global brands Calbiochem(R), Novabiochem(R), and Novagen(R), today announced a unique addition to its catalog of research reagents: the first in vitro-derived, recombinant antibody (www.preview.emdbiosciences.com/product/ST1071). This antibody is targeted against human Cyclophilin A and is produced by MorphoSys' Antibodies by Design (www.a-by-d.com) division, a provider of rapid, high-throughput custom antibody reagent services for the academic and industrial research markets. EMD Biosciences is part of the Life Science and Analytics (LSA) division of Merck KGaA (Darmstadt, Germany; www.merck.de) and operates as EMD Biosciences, Inc. in North America and Merck Biosciences outside North America. Distribution of additional recombinant antibodies is planned under the collaboration. MorphoSys' Antibodies by Design division produces the antibodies using its HuCAL GOLD(R) library.
comments powered by